EUVIMEDEUVIMED entdecken
Crossref

Advances in mTOR Inhibitors for Cancer Treatment

Navaneetha Krishnan T S, Chagaleti Bharath Kumar, Gandi Sony Pears

ChemistrySelect · 2026-11 · 11 (43)

DOI: 10.1002/slct.75157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 16.11.2026. Verfasst von Navaneetha Krishnan T S und 2 weiteren Autor:innen. Die Arbeit nennt 146 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mechanistic target of rapamycin (mTOR) is a conserved serine/threonine protein kinase that regulates cellular growth, metabolism, proliferation, and survival by integrating nutrient availability, growth factor signaling, and intracellular stress responses. mTOR forms two distinct multiprotein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), which mediate its biological functions. mTOR signaling is aberrantly activated in many cancers and contributes to uncontrolled growth, metabolic repatterning, tumor blood vessel growth, immune evasion, progression, and therapy resistance. Thus, the mTOR pathway is an important target for cancer therapy. Over the past two decades, numerous natural and synthetic mTOR inhibitors have been identified. These inhibitors showed promising anticancer efficacy in preclinical studies and clinical trials. In this review, we discuss the structure and function of mTOR complexes, their role in cancer, and the chemistry, mechanisms, and applications of mTOR inhibitors, including rapalogs, ATP‐competitive inhibitors, and RapaLink compounds in mTOR‐resistant cells. We discussed mTOR inhibitors that are currently under clinical evaluation, emphasizing their progress in development, potential therapeutic applications, and clinical importance. Furthermore, we examined key investigational compounds at various stages of clinical trials to provide insights into novel therapeutic strategies and support the advancement of more effective mTOR‐targeted cancer treatments.

Zitieren

APA

S, N. K. T., Kumar, C. B., & Pears, G. S. (2026). Advances in mTOR Inhibitors for Cancer Treatment. ChemistrySelect, 11(43). https://doi.org/10.1002/slct.75157

Vancouver

S NKT, Kumar CB, Pears GS. Advances in mTOR Inhibitors for Cancer Treatment. ChemistrySelect. 2026;11(43). doi:10.1002/slct.75157

BibTeX
@article{S2026,
  author = {S, Navaneetha Krishnan T and Kumar, Chagaleti Bharath and Pears, Gandi Sony},
  title = {Advances in mTOR Inhibitors for Cancer Treatment},
  journal = {ChemistrySelect},
  year = {2026},
  volume = {11},
  number = {43},
  doi = {10.1002/slct.75157}
}
Kostenlos starten →